Orion and Alligator Bioscience agree on a change to the license agreement, which will change the license that previously included a royalty obligation into a perpetual, fully paid and royalty-free license for Orion.
Pharmaceutical company Orion and Alligator Bioscience have agreed to amend the license agreement concerning two bispecific antibodies that the companies have developed together.
Orion will continue to develop these antibodies in late pre-clinical development without any obligation to pay Alligator Bioscience any milestone payments or royalties.
In connection with the contract amendment, Orion will pay Alligator Bioscience a one-time payment of 3.5 million euros. For comparison: last year, Orion’s turnover was 1.2 billion euros.
Orion and Alligator Bioscience signed a research collaboration and license agreement in 2021. The goal was to jointly develop antibodies to treat cancer.
Source: www.arvopaperi.fi
